Study #2023-0576
A phase I study investigating the safety and efficacy of Danvatirsen as monotherapy followed by combination with Venetoclax in patients with relapsed/refractory MDS & AML
MD Anderson Study Status
Enrolling
Treatment Agent
Danvatirsen, Combination Product: Danvatirsen + Venetoclax
Description
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.